GleamWall
中文EN

TNYA Tenaya Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1858848 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-8.0%
TTM EPS YoY36.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-148.2%
ROA-112.1%
ROIC (approx.)-1,156.6%
Asset turnover—

Leverage & solvency

Liabilities / assets28.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio-52.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$68.61M$86.74M
SG&A expense$24.72M$29.21M
Operating income-$93.33M-$115.95M
Pretax income-$90.60M-$111.13M
Income tax$0$0
Net income-$90.60M-$111.13M
EBITDA-$84.89M-$107.48M
EPS (basic)-0.59-1.31
EPS (diluted)-0.59-1.31
Weighted avg. shares (diluted)152.97M84.82M
Balance sheet
Cash & equivalents$100.55M$4.32M
Short-term investments—$57.12M
Current assets$105.59M$67.38M
PP&E, net$27.67M$35.86M
Total assets$146.92M$119.94M
Current liabilities$15.44M$15.97M
Total liabilities$23.66M$27.09M
Shareholders' equity$123.27M$92.85M
Shares outstanding216.76M86.54M
Cash flow statement
Operating cash flow-$68.26M-$90.50M
Capital expenditure$618,000$1.02M
Free cash flow-$68.88M-$91.53M
Investing cash flow$56.08M$1.13M
Financing cash flow$108.41M$47.75M
Depreciation & amortization$8.44M$8.47M
Stock-based compensation$13.05M$16.50M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.